{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:08Z","timestamp":1791489548305,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":231,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101407","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:48:12Z","timestamp":1788814092000},"page":"101407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular characterization of salivary cancers: Patterns of genomic alterations and potential for impact on therapeutic choices"],"prefix":"10.1016","volume":"49","author":[{"given":"Marjan","family":"Kamali-Sarvestani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janessa","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ko-Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Sabag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Weymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Regier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-3984","authenticated-orcid":false,"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101407_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101407_bib0002","first-page":"597","article-title":"The evolving landscape of salivary gland tumors","volume":"73","author":"Steuer","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101407_bib0003","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2026.101407_bib0004","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101407_bib0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0006","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European reference network on rare adult solid cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMo Open"},{"key":"10.1016\/j.ctarc.2026.101407_bib0008","unstructured":"Illumina. AmpliSeq\u2122 for illumina focus panel targeted DNA and RNA panel investigating 52 genes with known relevance to solid tumors. Accessed 12 April 2026."},{"key":"10.1016\/j.ctarc.2026.101407_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ctarc.2026.101407_bib0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0011","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0012","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0013","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of Trastuzumab and Docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of Lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0016","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ctarc.2026.101407_bib0017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0018","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0019","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101407_bib0020","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101407_bib0021","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0022","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/cancers14174156","article-title":"Identification of fusion genes and targets for genetically matched therapies in a large cohort of salivary gland cancer patients","volume":"14","author":"Lassche","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101407_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1107134","article-title":"Targeted treatment in a case series of AR+, HRAS\/PIK3CA co-mutated salivary duct carcinoma","volume":"13","author":"Rieke","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0024","article-title":"Excellent response with Alpelisib and Bicalutamide for advanced salivary duct carcinoma with PIK3CA mutation and high androgen receptor expression- a case report","volume":"5","author":"Sheth","year":"2021","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101407_bib0025","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cancers14051133","article-title":"Evaluation of the clinical utility of genomic profiling to inform selection of clinical trial therapy in salivary gland cancer","volume":"14","author":"Rack","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:35:32Z","timestamp":1791488132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"alternative-id":["S2468294226003175"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101407","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of salivary cancers: Patterns of genomic alterations and potential for impact on therapeutic choices","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101407"}}